What Oncologists Say

What Oncologists Say

The DiviTum® TKa test has shown to be valuable in assessing oncology and immuno-oncology compounds. As an early efficacy assay for evaluating endocrine therapy and a strong pharmacodynamic tool for new, targeted drugs like CDK4/6 inhibitors, DiviTum® TKa can add value in disease monitoring and treatment. Read testimonials from experts.

Learn more about our clinical research

The DiviTum® TKa test has been widely studied, and multiple publications support its application to prognose, predict, and monitor breast cancer treatment response. You can learn more about our published studies and extensive breast cancer study program here.


Please specify your home location